[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Will This Jumpstart a New Uranium Boom Market?]( [Get the Full Story on Uranium Opportunities Here]( --------------------------------------------------------------- December 28, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [More, More, More & Nuclear Energy, That Is...]( "perfect storm" of factors is breathing new life into the nuclear energy sector. The U.S. is working hard to build more advanced nuclear plants to achieve clean energy and climate goals. However, America's reliance on Russia for uranium has grave implications for national security. Fortunately, billions of dollars in Govt. incentives are now up for grabs to help revive the domestic uranium industry. [See How Investors Could Benefit From the Nuclear "Renaissance"]( --------------------------------------------------------------- [Neovasc, NVCN]( Recent Analyst Action: Vernon Bernardino, analyst at H.C. Wainwright, reiterates coverage on [Neovasc (NVCN)](in the Healthcare sector with a Buy rating and a price target of $20.00 (1 month ago). - Recent Price: $16.54 - Average Analyst Price Target: $20.00 (20.92%) - Market Cap: $41.21M [TipRanks.com]( also reports that [Neovasc](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $20.00. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $20.00. [Neovasc (NVCN)](’s last closing price was $16.54 which would put the average price target at $20.00 . Here are 3rd party ratings for [NVCN](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 38% (93 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [These 2 Dividend Stocks Pay Every Week]( you still looking for consistent income in this near-zero interest rate environment? There is a better way. I just revealed the Holy Grail of dividend stocks - a safe, reliable and consistent stock that [pays dividends EVERY single week](- 52 times a year. It's simple: Buy the stock this Monday and you'll get your first dividend payout in your bank account this Thursday....and then every Thursday after for as long as you own the stock! [Tap here to reveal the name of this stock for FREE.]( --------------------------------------------------------------- [Xilio Therapeutics, XLO]( Recent Analyst Action: Matthew Barcus, analyst at Chardan Capital, reiterates coverage on [Xilio Therapeutics (XLO)](in the Healthcare sector with a Buy rating and a price target of $7.00 (1 week ago). - Recent Price: $2.38 - Average Analyst Price Target: $10.00 (320.17%) - Market Cap: $67.72M [TipRanks.com]( also reports that [Xilio Therapeutics](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.00. The target pricing ranges from a high forecast of $13.00 down to a low forecast of $7.00. [Xilio Therapeutics (XLO)](’s last closing price was $2.38 which would put the average price target at $10.00 . Here are 3rd party ratings for [XLO](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 27% (66 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Calithera Bio, CALA]( Recent Analyst Action: Aydin Huseynov, analyst at Ladenburg Thalmann & Co., reiterates coverage on [Calithera Bio (CALA)](in the Healthcare sector with a Hold rating (1 month ago). - Recent Price: $2.99 - Average Analyst Price Target: $5.00 (67.22%) - Market Cap: $14.16M [TipRanks.com]( also reports that [Calithera Bio](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.00. The target pricing ranges from a high forecast of $8.00 down to a low forecast of $2.00. [Calithera Bio (CALA)](’s last closing price was $2.99 which would put the average price target at $5.00 . Here are 3rd party ratings for [CALA](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 34% (85 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [New Documentary: The Two Men Destroying America]( This is causing a lot of controversy… It’s a new documentary called [The Two Men Destroying America.]( And a lot of powerful people would rather this exposé never saw the light of day. Chances are, they’ll attempt to have it scrubbed from existence. That’s because it tells the true (and terrifying) story of how two men from New York have engineered a reset of not just your personal wealth, but the entire US economic system. [Click play to watch The Two Men Destroying America]( --------------------------------------------------------------- [Energy Vault Holdings, NRGV]( Recent Analyst Action: Brian K., analyst at Goldman Sachs, reiterates coverage on [Energy Vault Holdings (NRGV)](in the Industrial Goods sector with a Sell rating and a price target of $2.5 (1 week ago). - Recent Price: $2.59 - Average Analyst Price Target: $6.17 (138.22%) - Market Cap: $363.65M [TipRanks.com]( also reports that [Energy Vault Holdings](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.17. The target pricing ranges from a high forecast of $9.00 down to a low forecast of $2.50. [Energy Vault Holdings (NRGV)](’s last closing price was $2.59 which would put the average price target at $6.17 . Here are 3rd party ratings for [NRGV](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Bottom 29% (175 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [EyePoint Pharmaceuticals, EYPT]( Recent Analyst Action: Yatin Suneja, analyst at Guggenheim, reiterates coverage on [EyePoint Pharmaceuticals (EYPT)](in the Healthcare sector with a Buy rating and a price target of $52.00 (1 month ago). - Recent Price: $3.14 - Average Analyst Price Target: $36.00 (1046.50%) - Market Cap: $102.59M [TipRanks.com]( also reports that [EyePoint Pharmaceuticals](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $36.00. The target pricing ranges from a high forecast of $52.00 down to a low forecast of $25.00. [EyePoint Pharmaceuticals (EYPT)](’s last closing price was $3.14 which would put the average price target at $36.00 . Here are 3rd party ratings for [EYPT](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 27% (66 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Military Defense Impacted by Domestic Uranium Shortage?]( people know that the U.S. military's nuclear fleet is the largest uranium fuel consumer in the world. About 160 U.S. ships are powered by over 200 small nuclear reactors. While most are submarines, some icebreakers and aircraft carriers are also nuclear-powered. Unfortunately, current U.S. reliance on Russian state-owned sources for our uranium supply leaves our entire nuclear energy sector - including defense - vulnerable to geopolitical conflict such as Russia's war against Ukraine. [See the Factors Creating New Uranium Investment Opportunities]( --------------------------------------------------------------- [CymaBay Therapeutics, CBAY]( Recent Analyst Action: Mayank Mamtani, analyst at B.Riley Financial, reiterates coverage on [CymaBay Therapeutics (CBAY)](in the Healthcare sector with a Buy rating and a price target of $8.00 (2 weeks ago). - Recent Price: $5.51 - Average Analyst Price Target: $9.20 (66.97%) - Market Cap: $467.44M [TipRanks.com]( also reports that [CymaBay Therapeutics](currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.20. The target pricing ranges from a high forecast of $10.00 down to a low forecast of $8.00. [CymaBay Therapeutics (CBAY)](’s last closing price was $5.51 which would put the average price target at $9.20 . Here are 3rd party ratings for [CBAY](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 26% (64 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [CVRX, CVRX]( Recent Analyst Action: Robbie Marcus, analyst at J.P. Morgan, reiterates coverage on [CVRX (CVRX)](in the Healthcare sector with a Buy rating and a price target of $17.00 (2 weeks ago). - Recent Price: $17.35 - Average Analyst Price Target: $15.50 (-10.66%) - Market Cap: $355.08M [TipRanks.com]( also reports that [CVRX](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.50. The target pricing ranges from a high forecast of $17.00 down to a low forecast of $14.00. [CVRX (CVRX)](’s last closing price was $17.35 which would put the average price target at $15.50 . Here are 3rd party ratings for [CVRX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 38% (93 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Nobel Prize Winner's Premonition About Nuclear Energy Comes True]( Prize-winning physicist Dr. Burton Richter made a controversial statement 15 years ago. Despite skepticism, he predicted that more nuclear power was needed to help combat the damaging effects of a changing climate. As it turns out, he was correct... Experts now advise that nuclear power is the ONLY realistic way for the world to meet climate goals and achieve energy independence. [Will This Nuclear Revival Send Uranium On a New Bull Run?]( --------------------------------------------------------------- And there you have it--7 Five Day Gainers across all US Exchanges. Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software